Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Pharmacogenomics: mapping monogenic mutations to direct therapy
Palmer Taylor
Palmer Taylor
Published June 25, 2012
Citation Information: J Clin Invest. 2012;122(7):2356-2358. https://doi.org/10.1172/JCI64409.
View: Text | PDF
Commentary

Pharmacogenomics: mapping monogenic mutations to direct therapy

  • Text
  • PDF
Abstract

The molecular mapping of mutations that underlie congenital disorders of monogenic origin can result in both a broader understanding of the molecular basis of the disorder and novel therapeutic insights. Indeed, genotyping patients and then replicating the behavior of the mutant gene products in well-defined biochemical or electrophysiological systems will allow tailoring of therapy to be mutation- and protein sequence–dependent. In this issue of the JCI, Shen and colleagues describe such an approach that identified novel mutations in the α subunit of the nicotinic receptor linked to myasthenia gravis.

Authors

Palmer Taylor

×

Figure 1

Space-filling structure of the muscle nicotinic acetylcholine receptor (m-nAChR).

Options: View larger image (or click on image) Download as PowerPoint
Space-filling structure of the muscle nicotinic acetylcholine receptor (...
Shown is a representation of the muscle nAChR from the Torpedo sp. electric organ based on the electron microscopy reconstructions of Unwin (13). The pentameric structure in Torpedo and mammalian skeletal muscle consists of two copies of an α subunit, one β, one δ, and one γ or ε, depending on whether the muscle receptor is innervated. The portion between the two parallel dark gray sheets represents the transmembrane span. Acetylcholine binds cooperatively at the α-γ and α-δ subunit interfaces, as shown by the radial entry of the blue arrow, causing the channel gate, located in the transmembrane span, to open. Ion entry is shown by the gray arrow leading into a central vestibule of the channel surrounded by the five subunits. The structure is based on ref. 14 (Protein Data Bank [PDB] 2BG9). The insets show ribbon diagrams of portions of the α subunit where the two mutations, G74C and V188M, reside. Also shown in the lower inset in white, with red denoting oxygen and blue nitrogen, are the aromatic side chains Y190 and Y93 and charged side chains D200 and K145, forming the proposed tetrad of interacting side chains involved in activation (1). The diagrams are based on a crystal structure of the α1 subunit from mouse complexed with the snake toxin α-bungarotoxin (ref. 15; PDB 2QC1). The toxin structure has been removed for clarity.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts